This role of BAFF is evident not only in BAFF-overexpressing mice, which develop autoimmune-like symptoms and B-cell lymphoproliferative disorders, but also in CLL patients treated with venetoclax or the anti-CD20 antibody Obinutuzumab showing markedly elevated levels of BAFF, leading to sustained pro-survival protein expression in leukemic cells over time [79,80]. This evidence concerns the gene TNFSF13B and B-cell chronic lymphocytic leukemia.